Association for Research in Vision and Ophthalmology (ARVO) 2026
Topographic forecasting of geographic atrophy progression from OCT-derived retinal biomarker maps using a neural ODE framework
Earlier treatment yields better outcomes: 5-years of pegcetacoplan treatment for geographic atrophy secondary to AMD
First time phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to age-related macular degeneration
Ellipsoid zone loss in isolation and outer nuclear layer are photoreceptor integrity endpoints that predict future visual decline in geographic atrophy
Factors affecting disease progression and vision loss in geographic atrophy: Findings from OAKS and DERBY
Longitudinal aqueous humor complement protein dynamics in patients with geographic atrophy receiving intravitreal pegcetacoplan
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
